Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.

Low α2-macroglobulin, impaired fibrinolysis up risk of asthma exacerbation

14 Sep 2017

Lower plasma levels of α2-macroglobulin and impaired fibrinolysis appear to increase the risk of asthma exacerbations, a new study has shown.

In the study sample of 157 patients with asthma, 198 severe asthma exacerbations were recorded, corresponding to 64 events per year. These were observed in 34 percent (n=53) of the patients, of whom 33 had at least three complication events.

Those who experienced exacerbations were significantly older (p=0.004), had longer asthma duration (p=0.006) and worse asthma control (p=0.02). Those with exacerbations also showed significantly lower forced expiratory volumes in 1 second (p=0.01) compared with controls.

Interestingly, in those who experienced at least one exacerbation, clot lysis time (CLT) was significantly longer (p=0.038) and α2-macroglobulin levels were significantly lower (p=0.04) after controlling for potential confounders.

Even in moderate and severe asthmatics (n=47), at least one case of asthma exacerbation was association with significantly higher CLT (p=0.002) and lower α2-macroglobulin (p=0.04).

In multiple logistic regression analysis, asthma duration (odds ratio [OR], 1.037; 95 percent CI, 1.011 to 1.065; p=0.006), asthma control test (OR, 0.971; 0.905 to 0.999; p=0.046), CLT (OR, 1.007; 1.001 to 1.013; p=0.049) and α2-macroglobulin (OR, 0.938; 0.886 to 0.992; p=0.025) were all identified as independent predictors of exacerbated asthmatic events.

The most important factors that contribute to the risk of asthma exacerbation were severe asthma (relative risk [RR], 1.55; 1.19 to 2.03; p<0.0001), oral corticosteroids at baseline (RR, 2.15; 1.49 to 3.11; p<0.0001) and gastroesophageal reflux disease (RR, 2.5; 1.7 to 3.61; p<0.0001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.